These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 27889192)

  • 1. Evolving concepts in the treatment of relapsing multiple sclerosis.
    Comi G; Radaelli M; Soelberg Sørensen P
    Lancet; 2017 Apr; 389(10076):1347-1356. PubMed ID: 27889192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory therapies for relapsing-remitting multiple sclerosis: monoclonal antibodies, currently approved and in testing.
    Craddock J; Markovic-Plese S
    Expert Rev Clin Pharmacol; 2015 May; 8(3):283-96. PubMed ID: 25916665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
    Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
    Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
    Vidal-Jordana A; Montalban X
    Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.
    Bayry J; Hartung HP; Kaveri SV
    Trends Pharmacol Sci; 2015 Jul; 36(7):419-21. PubMed ID: 26003802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line therapy in relapsing remitting multiple sclerosis.
    Biotti D; Ciron J
    Rev Neurol (Paris); 2018 Jun; 174(6):419-428. PubMed ID: 29703445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM
    N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract]   [Full Text] [Related]  

  • 13. Current management of relapsing-remitting multiple sclerosis.
    Sedal L; Wilson IB; McDonald EA
    Intern Med J; 2014 Oct; 44(10):950-7. PubMed ID: 25302718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of monoclonal antibodies for the treatment of multiple sclerosis.
    McGinley MP; Moss BP; Cohen JA
    Expert Opin Drug Saf; 2017 Jan; 16(1):89-100. PubMed ID: 27756172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM; Rainka MM; Patel MJ; Gengo FM
    Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.